
TRIMTECH raises $47m for protein degradation portfolio
TRIMTECH Therapeutics has raised an additional $14 million in seed funding, bringing total investment for the company’s targeted protein degradation portfolio to $47 million. TRIMTECH has demonstrated its TRIMTAC and TRIMGLUE degraders can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these proteins intact to… Read More



